Abstract:Hepatic stellate cells (HSCs) are activated with chronic liver injury and transdifferentiate into myofibroblasts, which produce excessive extracellular matrices that form the fibrotic scar. While the progression of fibrosis is understood to be the cause of end-stage liver disease, there are no approved therapies directed at interfering with the activity of HSC myofibroblasts. We performed a high-throughput small interfering RNA (siRNA) screen in primary human HSC myofibroblasts to identify gene products necessary for the fibrotic phenotype of HSCs. We found that depletion of promotes the inactivation of HSCs, characterized by reduced and expression and accumulation of lipid droplets. Mice deficient for are also protected from fibrosis in the setting of liver injury. While ABHD17B is a depalmitoylase, our data suggest that ABHD17B promotes fibrosis through pathways independent of depalmitoylation that include interaction with MYO1B to modulate gene expression and HSC migration. Together, our results provide an analysis of the phenotypic consequences for siRNAs targeting RNAs from >9,500 genes in primary human HSCs and identify ABHD17B as a potential therapeutic target to inhibit liver fibrosis.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify targets that can inhibit fibrosis in hepatic stellate cells (HSCs). Specifically, the study uses a high - throughput small interfering RNA (siRNA) screening method to search for gene products that can promote the inactivation of HSCs in human primary HSCs. The study finds that the depletion of ABHD17B can promote the inactivation of HSCs, which is manifested as a reduction in the expression of type I collagen (COL1A1) and α - smooth muscle actin (ACTA2), accompanied by an increase in lipid droplet accumulation. In addition, ABHD17B - knockout mice are protected from fibrosis under liver injury conditions. These results suggest that ABHD17B may be a potential target for the treatment of liver fibrosis. ### Main research questions: 1. **Identify potential targets for inhibiting liver fibrosis**: Through siRNA screening, identify genes that play a key role in HSCs, especially those that can promote the inactivation of HSCs. 2. **Verify the function of ABHD17B**: Confirm the role of ABHD17B in HSCs, especially in the fibrosis process. 3. **Explore the mechanism of action of ABHD17B**: Study how ABHD17B affects the activation state of HSCs, as well as its role in cell migration and gene expression regulation. ### Research methods: - **High - throughput siRNA screening**: Conduct siRNA screening in human primary HSCs to identify genes that can promote the inactivation of HSCs. - **Functional verification**: Verify the function of ABHD17B through various experimental techniques (such as qRT - PCR, immunofluorescence staining, cell migration experiments, etc.). - **In vivo experiments**: Use the ABHD17B - knockout mouse model to evaluate the role of ABHD17B in the development of liver fibrosis. ### Key findings: - **Depletion of ABHD17B promotes HSCs inactivation**: Depletion of ABHD17B leads to a reduction in the expression of COL1A1 and ACTA2 in HSCs, accompanied by an increase in lipid droplet accumulation. - **ABHD17B - knockout mice are protected from fibrosis**: ABHD17B - knockout mice show protection against fibrosis under liver injury conditions. - **ABHD17B interacts with MYO1B**: ABHD17B interacts with MYO1B to jointly regulate the migration of HSCs and the expression of COL1A1. These findings provide potential targets and a mechanistic basis for the development of new liver fibrosis treatment methods.

Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cells

Genome-wide CRISPR Screening to Identify Drivers of TGF-β-Induced Liver Fibrosis in Human Hepatic Stellate Cells

An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis

Expanded transcriptomic analysis of human hepatic stellate cells links novel coding and noncoding products to human liver fibrosis

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis

Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis

Orphan receptor GPR176 in hepatic stellate cells exerts a profibrotic role in chronic liver disease

Effects of Sirna Targeting ADAMTS2 Gene on Hepatic Stellate Cells

The Inhibitory Effects of Hjc0416 on Liver Fibrogenesis in Activated Hepatic Stellate Cells

Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells

11βHSD1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.

Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice

Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis

Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures

Identification of Liver Fibrosis-Related MicroRNAs in Human Primary Hepatic Stellate Cells Using High-Throughput Sequencing

Hab18g/Cd147 Promotes Activation of Hepatic Stellate Cells and is A Target for Antibody Therapy of Liver Fibrosis

P70 Ribosomal Protein S6 Kinase is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice.

SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9

The miR-23b/27b/24-1 Cluster Inhibits Hepatic Fibrosis by Inactivating Hepatic Stellate Cells

Hepatic Stellate Cell Membrane-Camouflaged Nanoparticles for Targeted Delivery of an Antifibrotic Agent to Hepatic Stellate Cells with Enhanced Antifibrosis Efficacy.